Nordic Life Science 1
measuring a unique panel of metabolites whose com
position has been found to be altered in the blood and urine of cancer patients, allowing identification of distinct “signatures” using machine learning. These signatures, or biomarkers, are exceptionally sensitive and can be identified for a variety of cancers. At the beginning of 2019 the company became one of the winners in the EU program Horizon 2020 SME instrument phase 2 and was awarded EUR 2.35 million. This year, Elypta’s co-founder and CSO, Francesco Gatto, was named Pioneer of the Year at MIT Technology Review’s European Innovators Under 35 Summit in Paris. In September, the company was also the winner of the Nordic Life Science Award (both in the Delegate’s and the Business category). Nordic Life Science (NLS) asked Karl Bergman (KB), CEO of Elypta, about the company’s business strategy and what’s next. NORDICLIFESCIENCE.ORG 19